210 related articles for article (PubMed ID: 18278494)
1. Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors.
Thomas DL; Kranz DM; Roy EJ
Cancer Immunol Immunother; 2008 Sep; 57(9):1323-33. PubMed ID: 18278494
[TBL] [Abstract][Full Text] [Related]
2. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
3. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.
Preynat-Seauve O; Contassot E; Schuler P; Piguet V; French LE; Huard B
Cancer Res; 2007 May; 67(10):5009-16. PubMed ID: 17510433
[TBL] [Abstract][Full Text] [Related]
4. Response of T and B lymphocytes in the spleen, lymph nodes and mammary tumors in rats treated with human soluble tumor-associated antigens and commercial human albumin.
Ben-Hur H; Kossoy G; Mehrdad H; Elhayany A; Zusman I
Oncol Rep; 2004 Dec; 12(6):1329-33. PubMed ID: 15547759
[TBL] [Abstract][Full Text] [Related]
5. Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors.
Iwadate Y; Tagawa M; Namba H; Oga M; Kawamura K; Tasaki K; Sakiyama S; Yamaura A
Cancer Gene Ther; 2000 Sep; 7(9):1263-9. PubMed ID: 11023199
[TBL] [Abstract][Full Text] [Related]
6. Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection.
Petersen CC; Petersen MS; Agger R; Hokland ME
J Immunother; 2006; 29(3):241-9. PubMed ID: 16699367
[TBL] [Abstract][Full Text] [Related]
7. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.
Berraondo P; Nouzé C; Préville X; Ladant D; Leclerc C
Cancer Res; 2007 Sep; 67(18):8847-55. PubMed ID: 17875726
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model.
Kikuchi T; Akasaki Y; Abe T; Ohno T
Cancer Immunol Immunother; 2002 Oct; 51(8):424-30. PubMed ID: 12202903
[TBL] [Abstract][Full Text] [Related]
9. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.
Qiao J; Kottke T; Willmon C; Galivo F; Wongthida P; Diaz RM; Thompson J; Ryno P; Barber GN; Chester J; Selby P; Harrington K; Melcher A; Vile RG
Nat Med; 2008 Jan; 14(1):37-44. PubMed ID: 18066076
[TBL] [Abstract][Full Text] [Related]
10. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.
Driessens G; Gordower L; Nuttin L; Stordeur P; Blocklet D; Egrise D; Velu T; Bruyns C
Cancer Immunol Immunother; 2008 Dec; 57(12):1745-56. PubMed ID: 18369621
[TBL] [Abstract][Full Text] [Related]
12. Traffic to lymph nodes of PC-3 prostate tumor cells in nude mice visualized using the luciferase gene as a tumor cell marker.
Rubio N; Villacampa MM; Blanco J
Lab Invest; 1998 Oct; 78(10):1315-25. PubMed ID: 9800957
[TBL] [Abstract][Full Text] [Related]
13. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
14. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
15. Brain tumor inhibition in experimental model by restorative immunotherapy with a corpuscular antigen.
Gangopaddhyay SK; Sarkar S; Begum Z; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2003 Aug; 41(8):805-13. PubMed ID: 15248476
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with T11TS / S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status.
Mukherjee J; Ghosh A; Sarkar P; Mazumdar M; Banerjee C; Chaudhuri S
Anticancer Res; 2005; 25(4):2905-19. PubMed ID: 16080544
[TBL] [Abstract][Full Text] [Related]
17. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells.
Oizumi S; Deyev V; Yamazaki K; Schreiber T; Strbo N; Rosenblatt J; Podack ER
J Immunother; 2008 May; 31(4):394-401. PubMed ID: 18391756
[TBL] [Abstract][Full Text] [Related]
18. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
19. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses.
Dominguez AL; Lustgarten J
Cancer Res; 2008 Jul; 68(13):5423-31. PubMed ID: 18593945
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer.
Papewalis C; Wuttke M; Seissler J; Meyer Y; Kessler C; Jacobs B; Ullrich E; Willenberg HS; Schinner S; Baehring T; Scherbaum WA; Schott M
Clin Cancer Res; 2008 Jul; 14(13):4298-305. PubMed ID: 18594013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
